A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of S-297995 for the Treatment of Opioid-Induced Constipation in Subjects With Non-Malignant Chronic Pain Receiving Opioid Therapy.

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of S-297995 for the Treatment of Opioid-Induced Constipation in Subjects With Non-Malignant Chronic Pain Receiving Opioid Therapy.

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Jun 2017

At a glance

  • Drugs Naldemedine (Primary)
  • Indications Constipation
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 May 2015 According to Shionogi media release, data will be presented as a late-breaker abstract at the Digestive Disease Week meeting.
    • 19 May 2015 Primary endpoint has been met (Spontaneous bowel movement), as reported in Shionogi media release.
    • 19 May 2015 Results published in the Shionogi media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top